🏛️ Verified NIH Record • Updated 2025-10-10

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) (NCT06940440)

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: TuHURA Biosciences, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.

Who can join: Review the eligibility criteria below.

Location: H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

  • H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
  • University of Wisconsin Carbone Cancer Center — Madison, Wisconsin

📞 Contact the Study Coordinator

Phone: (813) 875-6600

Email: jbianco@tuhurabio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Or Metastatic Merkel Cell Carcinoma

Explore by condition: All Advanced Or Metastatic Merkel Cell Carcinoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗